These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30972998)

  • 21. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
    Müller T; Gessi M; Waha A; Isselstein LJ; Luxen D; Freihoff D; Freihoff J; Becker A; Simon M; Hammes J; Denkhaus D; zur Mühlen A; Pietsch T; Waha A
    Am J Pathol; 2012 Aug; 181(2):675-83. PubMed ID: 22688054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain.
    Coppieters N; Dieriks BV; Lill C; Faull RL; Curtis MA; Dragunow M
    Neurobiol Aging; 2014 Jun; 35(6):1334-44. PubMed ID: 24387984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus: further support for epigenetic mechanisms.
    Gambichler T; Terras S; Kreuter A; Skrygan M
    Br J Dermatol; 2014 Mar; 170(3):687-93. PubMed ID: 24164308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation.
    Szatkowski D; Hellmann A
    Acta Haematol; 2015; 133(1):116-23. PubMed ID: 25247397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytosine modifications in myeloid malignancies.
    Meldi KM; Figueroa ME
    Pharmacol Ther; 2015 Aug; 152():42-53. PubMed ID: 25956466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer.
    Kinney SR; Pradhan S
    Adv Exp Med Biol; 2013; 754():57-79. PubMed ID: 22956496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
    Poole CJ; Lodh A; Choi JH; van Riggelen J
    Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
    Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
    Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.
    Shao J; Wang S; West-Szymanski D; Karpus J; Shah S; Ganguly S; Smith J; Zu Y; He C; Li Z
    Sci Rep; 2022 Jul; 12(1):12410. PubMed ID: 35859008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation.
    Ficz G; Branco MR; Seisenberger S; Santos F; Krueger F; Hore TA; Marques CJ; Andrews S; Reik W
    Nature; 2011 May; 473(7347):398-402. PubMed ID: 21460836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
    Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Analysis of DNA Methylation, Hydroxymethylation, and Gene Expression Data Using ME-Class2.
    Singh MK; Edwards JR
    Methods Mol Biol; 2021; 2198():467-489. PubMed ID: 32822051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal Lead (Pb) Exposure and Peripheral Blood DNA Methylation (5mC) and Hydroxymethylation (5hmC) in Mexican Adolescents from the ELEMENT Birth Cohort.
    Rygiel CA; Goodrich JM; Solano-González M; Mercado-García A; Hu H; Téllez-Rojo MM; Peterson KE; Dolinoy DC
    Environ Health Perspect; 2021 Jun; 129(6):67002. PubMed ID: 34152198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
    Glowacka WK; Jain H; Okura M; Maimaitiming A; Mamatjan Y; Nejad R; Farooq H; Taylor MD; Aldape K; Kongkham P
    Acta Neuropathol; 2018 Apr; 135(4):617-634. PubMed ID: 29428975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
    Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.